{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:28:11Z","timestamp":1788920891460,"version":"build-2803163510"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"7th Framework Program of European Commission"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pharep.2014.12.017","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T16:45:26Z","timestamp":1421253926000},"page":"636-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Role of mTOR inhibitors in epilepsy treatment"],"prefix":"10.1007","volume":"67","author":[{"given":"Krzysztof","family":"Sadowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kotulska-J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.12.017_bib0665","unstructured":"WHO. Epilepsy. http:\/\/www.who.int\/mediacentre\/factsheets\/fs999\/en\/."},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0670","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1474-4422(10)70310-0","article-title":"Mechanisms of epileptogenesis and potential treatment targets","volume":"10","author":"Pitk\u00e4nen","year":"2011","journal-title":"Lancet Neurol"},{"issue":"17","key":"10.1016\/j.pharep.2014.12.017_bib0675","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1212\/WNL.0000000000000922","article-title":"mTOR: its role in the nervous system and involvement in neurologic disease","volume":"83","author":"Child","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib0680","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr Opin Cell Biol"},{"issue":"10","key":"10.1016\/j.pharep.2014.12.017_bib0685","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J Antibiot"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib0690","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"issue":"6483","key":"10.1016\/j.pharep.2014.12.017_bib0695","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin\u2013receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0700","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib0705","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0092-8674(93)90144-F","article-title":"Target of rapamycin in yeast: TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression","volume":"73","author":"Kunz","year":"1993","journal-title":"Cell"},{"issue":"5022","key":"10.1016\/j.pharep.2014.12.017_bib0710","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0715","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1073\/pnas.022634399","article-title":"Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin","volume":"99","author":"Huffman","year":"2002","journal-title":"PNAS"},{"issue":"24","key":"10.1016\/j.pharep.2014.12.017_bib0720","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.0000130641.08705.45","article-title":"Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload","volume":"109","author":"Mc Mullen","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib0725","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat Genet"},{"issue":"5233","key":"10.1016\/j.pharep.2014.12.017_bib0730","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.270.5233.50","article-title":"PIK-related kinases: DNA repair, recombination and cell cycle checkpoints","volume":"270","author":"Keith","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0735","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90058-6","article-title":"TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin","volume":"82","author":"Zheng","year":"1995","journal-title":"Cell"},{"issue":"5272","key":"10.1016\/j.pharep.2014.12.017_bib0740","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12\u2013rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0745","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ng1095-115","article-title":"HEAT repeats in the Huntington's disease protein","volume":"11","author":"Andrade","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0750","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0755","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-8674(02)01009-7","article-title":"Identification of TOR signaling complexes: more TORC for the cell growth engine","volume":"111","author":"Abraham","year":"2002","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.pharep.2014.12.017_bib0760","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cub.2006.08.001","article-title":"mSin1 is necessary for Akt\/PKB phosphorylation: and its isoforms define three distinct mTORC2s","volume":"16","author":"Frias","year":"2006","journal-title":"Curr Biol"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib0765","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2011.02.014","article-title":"Activation of mTORC2 by association with the ribosome","volume":"144","author":"Zinzalla","year":"2011","journal-title":"Cell"},{"issue":"5712","key":"10.1016\/j.pharep.2014.12.017_bib0770","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharep.2014.12.017_bib0775","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib0780","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.molcel.2013.08.019","article-title":"TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks","volume":"51","author":"Shimada","year":"2013","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0785","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0790","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0795","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci"},{"issue":"9","key":"10.1016\/j.pharep.2014.12.017_bib0800","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"9","key":"10.1016\/j.pharep.2014.12.017_bib0805","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0962-8924(03)00175-2","article-title":"PTEN: from pathology to biology","volume":"13","author":"Sulis","year":"2003","journal-title":"Trends Cell Biol"},{"issue":"7","key":"10.1016\/j.pharep.2014.12.017_bib0810","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/brain\/awm100","article-title":"Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5","volume":"130","author":"Puffenberger","year":"2007","journal-title":"Brain"},{"issue":"15","key":"10.1016\/j.pharep.2014.12.017_bib0815","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products: tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0820","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/MMBR.69.1.79-100.2005","article-title":"Signaling by target of rapamycin proteins in cell growth control","volume":"69","author":"Inoki","year":"2005","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib0825","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.pharep.2014.12.017_bib0830","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev"},{"issue":"23","key":"10.1016\/j.pharep.2014.12.017_bib0835","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1073\/pnas.0502857102","article-title":"The coordinate regulation of the p53 and mTOR pathways in cells","volume":"102","author":"Feng","year":"2005","journal-title":"PNAS"},{"issue":"13","key":"10.1016\/j.pharep.2014.12.017_bib0840","doi-asserted-by":"crossref","first-page":"10998","DOI":"10.1074\/jbc.M110.195016","article-title":"Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate","volume":"286","author":"Gan","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0845","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib0850","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.tig.2010.02.004","article-title":"Coordinated control of the gene expression machinery","volume":"26","author":"White","year":"2010","journal-title":"Trends Genet"},{"issue":"22","key":"10.1016\/j.pharep.2014.12.017_bib0855","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1073\/pnas.2132711100","article-title":"mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo","volume":"100","author":"Kwon","year":"2003","journal-title":"PNAS"},{"issue":"7","key":"10.1016\/j.pharep.2014.12.017_bib0860","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0092-8674(92)90643-Q","article-title":"Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases","volume":"69","author":"Chung","year":"1992","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib0865","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","article-title":"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1","volume":"95","author":"Burnett","year":"1998","journal-title":"PNAS"},{"issue":"12","key":"10.1016\/j.pharep.2014.12.017_bib0870","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib0875","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1158\/0008-5472.CAN-06-2875","article-title":"TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation","volume":"67","author":"Pelletier","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib0880","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.braindev.2006.09.009","article-title":"Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas","volume":"29","author":"J\u00f3\u017awiak","year":"2007","journal-title":"Brain Dev"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib0885","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nbd.2008.07.022","article-title":"Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury","volume":"32","author":"Carloni","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib0890","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharep.2014.12.017_bib0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2014.06.016","article-title":"Early molecular and behavioral response to lipopolysaccharide in the WAG\/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT\/mTOR pathways and neuroinflammatory cytokine release","author":"Russo","year":"2014","journal-title":"Brain Behav Immun"},{"issue":"12","key":"10.1016\/j.pharep.2014.12.017_bib0900","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.4049\/jimmunol.1303492","article-title":"mTOR signaling inhibition modulates macrophage\/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia","volume":"192","author":"Xie","year":"2014","journal-title":"J Immunol"},{"issue":"17","key":"10.1016\/j.pharep.2014.12.017_bib0905","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1874-6047(10)27017-8","article-title":"Chemistry and pharmacology of rapamycin and its derivatives","volume":"27","author":"Abraham","year":"2010","journal-title":"Enzymes"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"MTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib0915","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BJ20101024","article-title":"Characterization of PF-4708671: a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)","volume":"431","author":"Pearce","year":"2010","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0920","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1470-2045(07)70411-4","article-title":"Possible mechanisms of disease development in tuberous sclerosis","volume":"9","author":"J\u00f3\u017awiak","year":"2008","journal-title":"Lancet Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.pharep.2014.12.017_bib0925","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/hmg\/ddi260","article-title":"Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways","volume":"14","author":"Kwiatkowski","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"9639","key":"10.1016\/j.pharep.2014.12.017_bib0930","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharep.2014.12.017_bib0935","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.pharep.2014.12.017_bib0940","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","article-title":"Tuberous sclerosis","volume":"14","author":"Yates","year":"2006","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib0945","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/epi.12484","article-title":"Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis","volume":"55","author":"Humphrey","year":"2014","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib0950","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models","volume":"42","author":"Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"49","key":"10.1016\/j.pharep.2014.12.017_bib0955","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1523\/JNEUROSCI.2270-05.2005","article-title":"Control of dendritic arborization by the phosphoinositide-3\u2032-kinase-Akt-mammalian target of rapamycin pathway","volume":"25","author":"Jaworski","year":"2005","journal-title":"J Neurosci"},{"issue":"5796","key":"10.1016\/j.pharep.2014.12.017_bib0960","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1126\/science.1131693","article-title":"Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites","volume":"314","author":"Raab-Graham","year":"2006","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.pharep.2014.12.017_bib0965","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib0970","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib0975","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI7319","article-title":"Tsc2+\/\u2212 mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background","volume":"104","author":"Onda","year":"1999","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib0980","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1460-9568.2006.04594.x","article-title":"Impaired synaptic plasticity in a rat model of tuberous sclerosis","volume":"23","author":"von der Brelie","year":"2006","journal-title":"Eur J Neurosci"},{"issue":"8","key":"10.1016\/j.pharep.2014.12.017_bib0985","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib0990","doi-asserted-by":"crossref","first-page":"e35885","DOI":"10.1371\/journal.pone.0035885","article-title":"The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway","volume":"7","author":"Talos","year":"2012","journal-title":"PLoS ONE"},{"issue":"45","key":"10.1016\/j.pharep.2014.12.017_bib0995","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1073\/pnas.1106454108","article-title":"Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex","volume":"108","author":"Goto","year":"2011","journal-title":"PNAS"},{"issue":"23","key":"10.1016\/j.pharep.2014.12.017_bib1000","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1093\/hmg\/ddr393","article-title":"Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex","volume":"20","author":"Anderl","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharep.2014.12.017_bib1005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2012.11.003","article-title":"Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex","volume":"67","author":"Cambiaghi","year":"2013","journal-title":"Neuropharmacology"},{"issue":"14","key":"10.1016\/j.pharep.2014.12.017_bib1010","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1093\/hmg\/dds156","article-title":"The differential effects of prenatal and\/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex","volume":"21","author":"Way","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1015","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1528-1167.2008.01998.x","article-title":"Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience","volume":"50","author":"Lerner","year":"2009","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1528-1167.2010.02777.x","article-title":"The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission","volume":"52","author":"Bl\u00fcmcke","year":"2011","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib1025","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.20211","article-title":"mTOR cascade activation distinguishes tubers from focal cortical dysplasia","volume":"56","author":"Baybis","year":"2004","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10251","article-title":"Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis","volume":"52","author":"Becker","year":"2002","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1440-1789.2009.01018.x","article-title":"Increased frequency of distinct TSC2 allelic variants in focal cortical dysplasias with balloon cells and mineralization","volume":"29","author":"Sch\u00f6nberger","year":"2009","journal-title":"Neuropathology"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1040","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1528-1167.2008.01979.x","article-title":"Focal cortical dysplasia: a genotype-phenotype analysis of polymorphisms and mutations in the TSC genes","volume":"50","author":"Gumbinger","year":"2009","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1045","first-page":"43","article-title":"Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor's balloon cell type","volume":"46","author":"Grajkowska","year":"2008","journal-title":"Folia Neuropathol"},{"issue":"Suppl. 3","key":"10.1016\/j.pharep.2014.12.017_bib1050","first-page":"166","article-title":"Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II","volume":"51","author":"Cepeda","year":"2010","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1055","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ana.23795","article-title":"Detection of human papillomavirus in human focal cortical dysplasia type IIB","volume":"72","author":"Chen","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharep.2014.12.017_bib1060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2051-5960-2-71","article-title":"Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies","volume":"2","author":"Liu","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib1065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.seizure.2007.11.001","article-title":"Proteus syndrome associated with hemimegalencephaly and Ohtahara syndrome: report of two cases","volume":"17","author":"Bastos","year":"2008","journal-title":"Seizure"},{"issue":"22","key":"10.1016\/j.pharep.2014.12.017_bib1070","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1073\/pnas.2132711100","article-title":"mTOR is required for hypertrophy of Pten-deficient neuronal soma in vivo","volume":"100","author":"Kwon","year":"2003","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1523\/JNEUROSCI.5685-08.2009","article-title":"Pharmacological inhibition of mTORC1 suppresses anatomical: cellular, and behavioral abnormalities in neural-specific Pten knock-out mice","volume":"29","author":"Zhou","year":"2009","journal-title":"J Neurosci"},{"issue":"182","key":"10.1016\/j.pharep.2014.12.017_bib1080","doi-asserted-by":"crossref","first-page":"182ra53","DOI":"10.1126\/scitranslmed.3005271","article-title":"Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder","volume":"5","author":"Parker","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharep.2014.12.017_bib1085","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/9780470994030.ch18","article-title":"Focal brain malformations: a spectrum of disorders along the mTOR cascade","volume":"288","author":"Crino","year":"2007","journal-title":"Novartis Found Symp"},{"issue":"12","key":"10.1016\/j.pharep.2014.12.017_bib1090","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.molmed.2011.07.008","article-title":"mTOR: a pathogenic signaling pathway in developmental brain malformations","volume":"17","author":"Crino","year":"2011","journal-title":"Trends Mol Med"},{"issue":"38","key":"10.1016\/j.pharep.2014.12.017_bib1095","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1073\/pnas.1019012108","article-title":"Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC\/Rheb-independent manner","volume":"108","author":"Banerjee","year":"2011","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib1100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/lrb.2007.1012","article-title":"Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo","volume":"5","author":"Shirazi","year":"2007","journal-title":"Lymphat Res Biol"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3171\/2010.8.PEDS10145","article-title":"Surgical outcome for focal cortical dysplasia: an analysis of recent surgical series","volume":"6","author":"Chern","year":"2010","journal-title":"J Neurosurg Pediatr"},{"issue":"8","key":"10.1016\/j.pharep.2014.12.017_bib1110","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/j.1528-1167.2007.01112.x","article-title":"Surgical outcome in tuberous sclerosis complex: a multicenter survey","volume":"48","author":"Madhavan","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1528-1167.2008.01814.x","article-title":"Are cortical tubers epileptogenic? Evidence from electrocorticography","volume":"50","author":"Major","year":"2009","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.pharep.2014.12.017_bib1120","article-title":"Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation","volume":"7","author":"Lasarge","year":"2014","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"10.1016\/j.pharep.2014.12.017_bib1125","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: a U.S. consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.pharep.2014.12.017_bib1130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.braindev.2013.10.008","article-title":"Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013","volume":"36","author":"Pavone","year":"2013","journal-title":"Brain Dev"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib1135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.nbd.2011.03.021","article-title":"A pulse rapamycin therapy for infantile spasms and associated cognitive decline","volume":"43","author":"Raffo","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.pharep.2014.12.017_bib1140","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1528-1167.2011.03220.x","article-title":"Validation of the rat model of cryptogenic infantile spasms","volume":"52","author":"Chachua","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharep.2014.12.017_bib1145","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0074-7742(02)49023-X","article-title":"Infantile spasms: criteria for an animal model","volume":"49","author":"Stafstrom","year":"2002","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pharep.2014.12.017_bib1150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(02)49003-4","article-title":"What is West syndrome","volume":"49","author":"Dulac","year":"2002","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"10.1016\/j.pharep.2014.12.017_bib1155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.braindev.2012.12.005","article-title":"Basic mechanisms of catastrophic epilepsy \u2013 overview from animal models","volume":"35","author":"Galanopoulou","year":"2013","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib1160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40263-014-0139-5","article-title":"Recent advances in the pharmacotherapy of infantile spasms","volume":"28","author":"Riikonen","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2010.05.024","article-title":"Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy","volume":"40","author":"Huang","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"25","key":"10.1016\/j.pharep.2014.12.017_bib1170","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1523\/JNEUROSCI.4179-08.2009","article-title":"Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy","volume":"29","author":"Buckmaster","year":"2009","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1175","doi-asserted-by":"crossref","first-page":"e64455","DOI":"10.1371\/journal.pone.0064455","article-title":"Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment","volume":"8","author":"Macias","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib1180","doi-asserted-by":"crossref","first-page":"e57808","DOI":"10.1371\/journal.pone.0057808","article-title":"Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage","volume":"8","author":"Brewster","year":"2013","journal-title":"PLOS ONE"},{"issue":"7","key":"10.1016\/j.pharep.2014.12.017_bib1185","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1528-1167.2012.03513.x","article-title":"Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood\u2013brain barrier leakage but not microglia activation","volume":"53","author":"van Vliet","year":"2012","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.pharep.2014.12.017_bib1190","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1523\/JNEUROSCI.0066-09.2009","article-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","volume":"29","author":"Zeng","year":"2009","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1195","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1523\/JNEUROSCI.4852-10.2011","article-title":"Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy","volume":"31","author":"Buckmaster","year":"2011","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib1200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neulet.2011.12.051","article-title":"Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy","volume":"509","author":"\u015aliwa","year":"2012","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nbd.2006.12.003","article-title":"Rapamycin is a neuroprotective treatment for traumatic brain injury","volume":"26","author":"Erlich","year":"2007","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib1210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/jcbfm.2011.131","article-title":"Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice","volume":"32","author":"Park","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2014.12.017_bib1215","article-title":"Rapamycin attenuates the increases in seizure susceptibility and neuronal excitability following neonatal seizures in rat","volume":"11","author":"Talos","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.pharep.2014.12.017_bib1220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuropharm.2012.09.019","article-title":"mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy","volume":"69","author":"Russo","year":"2013","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pharep.2014.12.017_bib1225","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s10072-014-1842-1","article-title":"The mTOR signaling pathway and neuronal stem\/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model","volume":"35","author":"Russo","year":"2014","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1230","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00467-011-1811-3","article-title":"Growth of kidney-transplanted pediatric patients treated with sirolimus","volume":"26","author":"Gonz\u00e1lez","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1016\/j.pharep.2014.12.017_bib1235","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00467-009-1215-9","article-title":"Growth failure associated with sirolimus: case report","volume":"24","author":"Rangel","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1240","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1245","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib1250","doi-asserted-by":"crossref","first-page":"e57445","DOI":"10.1371\/journal.pone.0057445","article-title":"Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex","volume":"8","author":"Zhang","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib1255","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.pharep.2014.12.017_bib1260","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"issue":"9861","key":"10.1016\/j.pharep.2014.12.017_bib1265","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"9869","key":"10.1016\/j.pharep.2014.12.017_bib1270","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib1275","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","article-title":"Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations","volume":"17","author":"J\u00f3\u017awiak","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"10.1016\/j.pharep.2014.12.017_bib1280","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizures frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.pharep.2014.12.017_bib1285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpn.2011.09.006","article-title":"Effective everolimus treatment of inoperable: life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex","volume":"16","author":"Perek-Polnik","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1290","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1295","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharep.2014.12.017_bib1300","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1305","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.pharep.2014.12.017_bib1310","first-page":"129","article-title":"Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report","volume":"45","author":"Wiemer-Kruel","year":"2014","journal-title":"Neuropediatrics"},{"issue":"3","key":"10.1016\/j.pharep.2014.12.017_bib1315","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","article-title":"Identification of new epilepsy treatments: issues in preclinical methodology","volume":"53","author":"Galanopoulou","year":"2012","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.pharep.2014.12.017_bib1320","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S173411401500002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S173411401500002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:53Z","timestamp":1752611753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.12.017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S173411401500002X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.12.017","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of mTOR inhibitors in epilepsy treatment","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}